- Home
- VGM vs CRMD Comparison
VGM vs CRMD Comparison
Compare VGM & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGM | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.7M | 618.2M |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VGM | CRMD |
|---|---|---|
| Price | $10.39 | $7.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 151.6K | ★ 930.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.71 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $9.37 | $6.13 |
| 52 Week High | $10.66 | $17.43 |
Technical Indicators
Market Signals| Indicator | VGM | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 51.29 |
| Support Level | $10.19 | $7.05 |
| Resistance Level | $10.53 | $8.53 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 69.71 | 34.66 |
Price Performance
Historical ComparisonAbout VGM Invesco Trust for Investment Grade Municipals (DE)
Invesco Trust for Investment Grade Municipals is active in the financial services sector. Its investment objective is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.